Client News

Newron announces H1 2023 results and provides R&D update

Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

Destiny Pharma: Publication of new data demonstrates significantly superior efficacy of XF-73 compared to a leading topical antibiotic against MRSA in skin infection models

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Destiny Pharma: Board changes including appointment of new CEO

leon-nanodrugs appoints Dr. Hans Frickel as Chief Executive Officer

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel

AATec Medical Announces its Launch with EUR 2.7 million in Seed Financing to Unlock the Therapeutic Potential of Alpha-1 Antitrypsin

Rentschler Biopharma: Dr. Dominik Kugelstadt joins Rentschler Biopharma as Head of Clinical and Commercial Manufacturing, Laupheim

Carbios announces the success of its capital increase with preferential subscription rights of approximately 141 million euros, the largest on Euronext Growth since 2015